

Catalog # 10-2990 MCC-950

CAS# 256373-96-3

N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide sodium salt CRID3; CP-456773 sodium salt

Lot # X106931

MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-1¹. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes². Blocks canonical and noncanonical NLRP3 activation at nanomolar concentrations³. Inhibits interleukin 1 β (IL-1 β) secretion *in vivo* and attenuates the severity of experimental autoimmune encephalomyelitis (an MS disease model)³. Disrupts the interaction between AIM2 and ASC in a reconstituted cell-free inflammasome⁴. A valuable new tool for exploring the pathophysiology of NLRP3.

- 1) Laliberte et al. (2003), Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing; J. Biol. Chem., **278** 16567
- 2) Coll et al. (2011), The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes; Clin. PLoS One, **6(12)** e29539
- 3) Coll et al. (2015), A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory disease; Nat. Med., **21** 248
- 4) Kaneko et al. (2015), Reconstituted AIM2 inflammasome in cell-free system; J. Immunol. Methods, 426 76

PHYSICAL DATA

Molecular Weight:	426.46
Molecular Formula:	C ₂₀ H ₂₃ N ₂ O ₅ S • Na
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 40 mg/ml), or Water (up to 30 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied, desiccated at -20°C for up to 2 years from the date of purchase. Solutions in
	DMSO or distilled water may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.